Cargando…

Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers

Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic het...

Descripción completa

Detalles Bibliográficos
Autores principales: Castelo Rueda, Maria Paulina, Zanon, Alessandra, Gilmozzi, Valentina, Lavdas, Alexandros A., Raftopoulou, Athina, Delcambre, Sylvie, Del Greco M, Fabiola, Klein, Christine, Grünewald, Anne, Pramstaller, Peter P., Hicks, Andrew A., Pichler, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113363/
https://www.ncbi.nlm.nih.gov/pubmed/37072441
http://dx.doi.org/10.1038/s41531-023-00499-9
_version_ 1785027823655714816
author Castelo Rueda, Maria Paulina
Zanon, Alessandra
Gilmozzi, Valentina
Lavdas, Alexandros A.
Raftopoulou, Athina
Delcambre, Sylvie
Del Greco M, Fabiola
Klein, Christine
Grünewald, Anne
Pramstaller, Peter P.
Hicks, Andrew A.
Pichler, Irene
author_facet Castelo Rueda, Maria Paulina
Zanon, Alessandra
Gilmozzi, Valentina
Lavdas, Alexandros A.
Raftopoulou, Athina
Delcambre, Sylvie
Del Greco M, Fabiola
Klein, Christine
Grünewald, Anne
Pramstaller, Peter P.
Hicks, Andrew A.
Pichler, Irene
author_sort Castelo Rueda, Maria Paulina
collection PubMed
description Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances.
format Online
Article
Text
id pubmed-10113363
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101133632023-04-20 Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers Castelo Rueda, Maria Paulina Zanon, Alessandra Gilmozzi, Valentina Lavdas, Alexandros A. Raftopoulou, Athina Delcambre, Sylvie Del Greco M, Fabiola Klein, Christine Grünewald, Anne Pramstaller, Peter P. Hicks, Andrew A. Pichler, Irene NPJ Parkinsons Dis Article Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances. Nature Publishing Group UK 2023-04-18 /pmc/articles/PMC10113363/ /pubmed/37072441 http://dx.doi.org/10.1038/s41531-023-00499-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Castelo Rueda, Maria Paulina
Zanon, Alessandra
Gilmozzi, Valentina
Lavdas, Alexandros A.
Raftopoulou, Athina
Delcambre, Sylvie
Del Greco M, Fabiola
Klein, Christine
Grünewald, Anne
Pramstaller, Peter P.
Hicks, Andrew A.
Pichler, Irene
Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title_full Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title_fullStr Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title_full_unstemmed Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title_short Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
title_sort molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous prkn variant carriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113363/
https://www.ncbi.nlm.nih.gov/pubmed/37072441
http://dx.doi.org/10.1038/s41531-023-00499-9
work_keys_str_mv AT casteloruedamariapaulina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT zanonalessandra molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT gilmozzivalentina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT lavdasalexandrosa molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT raftopoulouathina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT delcambresylvie molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT delgrecomfabiola molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT kleinchristine molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT grunewaldanne molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT pramstallerpeterp molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT hicksandrewa molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers
AT pichlerirene molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers